Bio­gen, Ei­sai re­fresh amy­loid hy­poth­e­sis with PhI­II show­ing Alzheimer's med slows cog­ni­tive de­cline

In the first look at Phase III da­ta for lecanemab, Ei­sai and Bio­gen’s fol­low-up Alzheimer’s drug to the em­bat­tled Aduhelm launch, re­sults show the drug passed with fly­ing col­ors on a test look­ing at mem­o­ry, prob­lem solv­ing and oth­er de­men­tia met­rics.

One of the most-watched Alzheimer’s ther­a­pies in the clin­ic, lecanemab met the study’s pri­ma­ry goal on the CDR-SB — Clin­i­cal De­men­tia Rat­ing-Sum of Box­es — giv­ing the biotech the con­fi­dence to ask for full ap­proval in the US, EU and Japan by next March 31. The ex­per­i­men­tal drug re­duced clin­i­cal de­cline on the scale by 27% com­pared to place­bo at 18 months, the com­pa­nies said Tues­day night East­ern time and Wednes­day morn­ing in Japan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER